Literature DB >> 27536680

Overview of the Pathogenesis of ANCA-Associated Vasculitis.

Hong Xiao1, Peiqi Hu1, Ronald J Falk1, J Charles Jennette1.   

Abstract

BACKGROUND: Antineutrophil cytoplasmic autoantibodies (ANCA) are associated with a spectrum of necrotizing vasculitis including granulomatosis with polyangiitis, microscopic polyangiitis, eosinophilic granulomatosis with polyangiitis, and renal-limited necrotizing and crescentic glomerulonephritis. Clinical observations and in vitro and in vivo experimental evidence strongly indicate that ANCA are pathogenic.
SUMMARY: The etiology and pathogenesis of ANCA-associated vasculitis (AAV) are multifactorial, with contributions from genetic factors, environmental exposures, infections, characteristics of the innate and adaptive immune system, and the intensity and duration of the injury. Acute vascular inflammation is induced when resting neutrophils that have ANCA autoantigens sequestered in cytoplasmic granules are exposed to priming factors - for example, cytokines induced by infection or phlogogenic factors released by complement activation - that cause the release of ANCA antigens on the surface of neutrophils and in the microenvironment around the neutrophils. ANCA bind to these ANCA antigens, which activates neutrophils by Fcγ receptor engagement and F(ab')2 binding at the neutrophil cell surface. ANCA-activated neutrophils release factors that activate the alternative complement pathway, which generates C5a, a chemoattractant for neutrophils; C5a also primes the arriving neutrophils for activation by ANCA. Activated neutrophils adhere to and penetrate vessel walls, and they release toxic oxygen radicals and destructive enzymes that cause apoptosis and necrosis of the neutrophils as well as of the adjacent vessel wall cells and matrix. KEY MESSAGES: Patients with active AAV have ongoing asynchronous onsets of countless acute lesions, with each lesion evolving through stereotypical phases within 1 or 2 weeks. Induction of remission results in termination of new waves of acute lesions and allows all lesions to progress to scarring or resolution.

Entities:  

Keywords:  ANCA; Antineutrophil cytoplasmic autoantibodies; Autoantibodies; Polyangiitis; Vasculitis

Year:  2015        PMID: 27536680      PMCID: PMC4934824          DOI: 10.1159/000442323

Source DB:  PubMed          Journal:  Kidney Dis (Basel)        ISSN: 2296-9357


  83 in total

Review 1.  Immune regulatory mechanisms in ANCA-associated vasculitides.

Authors:  Nikola Lepse; Wayel H Abdulahad; Cees G M Kallenberg; Peter Heeringa
Journal:  Autoimmun Rev       Date:  2011-08-11       Impact factor: 9.754

2.  Antineutrophil cytoplasmic antibodies induce monocyte IL-8 release. Role of surface proteinase-3, alpha1-antitrypsin, and Fcgamma receptors.

Authors:  D R Ralston; C B Marsh; M P Lowe; M D Wewers
Journal:  J Clin Invest       Date:  1997-09-15       Impact factor: 14.808

3.  Patients hospitalized because of small vessel vasculitides with renal involvement in the period 1975-95: organ involvement, anti-neutrophil cytoplasmic antibodies patterns, seasonal attack rates and fluctuation of annual frequencies.

Authors:  M Tidman; R Olander; C Svalander; D Danielsson
Journal:  J Intern Med       Date:  1998-08       Impact factor: 8.989

4.  Aggravation of anti-myeloperoxidase antibody-induced glomerulonephritis by bacterial lipopolysaccharide: role of tumor necrosis factor-alpha.

Authors:  Dennis Huugen; Hong Xiao; Anita van Esch; Ronald J Falk; Carine J Peutz-Kootstra; Wim A Buurman; Jan Willem Cohen Tervaert; J Charles Jennette; Peter Heeringa
Journal:  Am J Pathol       Date:  2005-07       Impact factor: 4.307

5.  Neonatal microscopic polyangiitis secondary to transfer of maternal myeloperoxidase-antineutrophil cytoplasmic antibody resulting in neonatal pulmonary hemorrhage and renal involvement.

Authors:  Priya J Bansal; Mary C Tobin
Journal:  Ann Allergy Asthma Immunol       Date:  2004-10       Impact factor: 6.347

6.  Bone marrow-derived cells are sufficient and necessary targets to mediate glomerulonephritis and vasculitis induced by anti-myeloperoxidase antibodies.

Authors:  Adrian Schreiber; Hong Xiao; Ronald J Falk; J Charles Jennette
Journal:  J Am Soc Nephrol       Date:  2006-11-15       Impact factor: 10.121

7.  Genetically determined severity of anti-myeloperoxidase glomerulonephritis.

Authors:  Hong Xiao; Dominic Ciavatta; David L Aylor; Peiqi Hu; Fernando Pardo-Manuel de Villena; Ronald J Falk; J Charles Jennette
Journal:  Am J Pathol       Date:  2013-02-04       Impact factor: 4.307

8.  Experimental autoimmune vasculitis: an animal model of anti-neutrophil cytoplasmic autoantibody-associated systemic vasculitis.

Authors:  Mark A Little; Lucy Smyth; Alan D Salama; Sriparna Mukherjee; Jennifer Smith; Dorian Haskard; Sussan Nourshargh; H Terence Cook; Charles D Pusey
Journal:  Am J Pathol       Date:  2009-03-05       Impact factor: 4.307

9.  Antineutrophil cytoplasmic autoantibodies against the murine homolog of proteinase 3 (Wegener autoantigen) are pathogenic in vivo.

Authors:  Heiko Pfister; Markus Ollert; Leopold F Fröhlich; Leticia Quintanilla-Martinez; Thomas V Colby; Ulrich Specks; Dieter E Jenne
Journal:  Blood       Date:  2004-05-18       Impact factor: 22.113

Review 10.  Trojan horses: drug culprits associated with antineutrophil cytoplasmic autoantibody (ANCA) vasculitis.

Authors:  William F Pendergraft; John L Niles
Journal:  Curr Opin Rheumatol       Date:  2014-01       Impact factor: 5.006

View more
  25 in total

Review 1.  Pulmonary Involvement in Systemic Vasculitis.

Authors:  Luis Felipe Flores-Suárez; Marco A Alba; Heidegger Mateos-Toledo; Natllely Ruiz
Journal:  Curr Rheumatol Rep       Date:  2017-09       Impact factor: 4.592

Review 2.  Pathogenesis of ANCA-Associated Pulmonary Vasculitis.

Authors:  Marco A Alba; J Charles Jennette; Ronald J Falk
Journal:  Semin Respir Crit Care Med       Date:  2018-11-07       Impact factor: 3.119

3.  ANCA Associated Mononeuritis Multiplex with Overlap in Vasculitic Syndromes.

Authors:  Ravi Anadure; Coimbatore Narayanan; Govindraj Varadraj; Bevinahalli Nandeesh
Journal:  J Clin Diagn Res       Date:  2017-01-01

4.  Clinicopathological analysis of ANCA-associated glomerulonephritis focusing on plasma cell infiltrate.

Authors:  Naoko Masuzawa; Ayako Nishimura; Yu Mihara; Keiichi Tamagaki; Eiichi Konishi
Journal:  Clin Exp Nephrol       Date:  2019-09-04       Impact factor: 2.801

Review 5.  Anti-neutrophil cytoplasmic antibodies and their clinical significance.

Authors:  Supaporn Suwanchote; Muanpetch Rachayon; Pongsawat Rodsaward; Jongkonnee Wongpiyabovorn; Tawatchai Deekajorndech; Helen L Wright; Steven W Edwards; Michael W Beresford; Pawinee Rerknimitr; Direkrit Chiewchengchol
Journal:  Clin Rheumatol       Date:  2018-03-10       Impact factor: 2.980

6.  Bowman's capsule provides a protective niche for podocytes from cytotoxic CD8+ T cells.

Authors:  Anqun Chen; Kyung Lee; Vivette D D'Agati; Chengguo Wei; Jia Fu; Tian-Jun Guan; John Cijiang He; Detlef Schlondorff; Judith Agudo
Journal:  J Clin Invest       Date:  2018-07-09       Impact factor: 14.808

7.  Alpha-1 Antitrypsin Therapy for Autoimmune Disorders.

Authors:  Sihong Song
Journal:  Chronic Obstr Pulm Dis       Date:  2018-10-05

8.  Gene Expression Pathways across Multiple Tissues in Antineutrophil Cytoplasmic Antibody-associated Vasculitis Reveal Core Pathways of Disease Pathology.

Authors:  Marcia A Friedman; Dongseok Choi; Stephen R Planck; James T Rosenbaum; Cailin H Sibley
Journal:  J Rheumatol       Date:  2019-01-15       Impact factor: 4.666

Review 9.  ANCA-associated vasculitis with renal involvement.

Authors:  Valentina Binda; Gabriella Moroni; Piergiorgio Messa
Journal:  J Nephrol       Date:  2017-05-30       Impact factor: 3.902

10.  Alterations in circulating lymphoid cell populations in systemic small vessel vasculitis are non-specific manifestations of renal injury.

Authors:  B Fazekas; A Moreno-Olivera; Y Kelly; P O'Hara; S Murray; A Kennedy; N Conlon; J Scott; A M Melo; F B Hickey; D Dooley; E C O'Brien; S Moran; D G Doherty; M A Little
Journal:  Clin Exp Immunol       Date:  2017-10-20       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.